Bruland Home
List of publications
Scientific projects
Selected papers
Curriculum vitae
Latest news
Alpharadin
Osteosarcoma
In the media
Collaboration
Web links
Lectures
Symposia
Cultural projects
Various activites
Clips & photos
Vintage fishing tackle
File exchange

 

 
Professor Øyvind S. Bruland
 

Professor Øyvind S. Bruland

 

Curriculum vitae

Curriculum vitae 2014: Øyvind Sverre Bruland

Vennerhagen, Sørkedalen 982, N-0758 OSLO, Norway
Born: December 14, 1952 in Oslo, Norway. Civil Status: Cohabitant, 3 children

E.mail: oyvind.bruland@medisin.uio.no Web: www.bruland.info

EDUCATION:  1971-76: Studies in Chemistry, Mathematics, Biology and Zoology, University of Trondheim and University of Oslo. 1976 : Cand.Mag. (Bachelor of Science), University of Oslo. 1974-79: Medical studies at University of Oslo. 1979: Cand. Med. (M.D.), University of Oslo. 1989: Dr. Med. (Ph.D.), University of Oslo 

LATEST POSITIONS HELD:

  • 1996-2004: Sect. Head & Consult. Oncologist, Dept. of Oncology, DNR 
  • 1999-2002: Professor of Clinical Oncology, University of Tromsø 
  • 2000-02: Scientific Chairman, 18th. UICC World Cancer Congress 
  • 2002-08: Professor of Clinical Oncology, University of Oslo 
  • 2003-06: Head of Clinical Research, Center for Research & Training in Radiation Oncology 
  • 2004 (January-May): Visiting Professor, Dept. of Pediatrics, Memorial Sloan Kettering Cancer Center, New York 
  • 2004-present: Senior Consultant Oncologist, Dept. of Oncology, DNR
  • 2005-2013: Professor of Comparative Oncology, (adjunct position), The Norwegian School of Veterinary Medicine, Oslo 
  • 2008-present: Professor of Clinical Oncology (Tenure position) University of Oslo 

SCIENTIFIC MERITS:

  • Publications: 153 papers in peer-reviewed international journals. In addition several editorials, reviews and book-chapters etc. For a complete list see List of Publications at www.bruland.info
  • On the "Editorial Board" of three scientific international journals
  • Holds five international patents related to targeted radionuclide therapies 
  • Founder of Algeta ASA in 1997 together with Roy H. Larsen - Their lead product Alpharadin (Radium-223); currently marketed by Bayer as Xofigo, was approved by FDA & EMA, 2013 for patients with skeletal metastases from prostate cancer. Phase-2 studies in breast cancer are ongoing 
  • 2008 - Elected member of The Norwegian Academy of Science and Letters - Det Norske Videnskaps-Akademi 
  • 2009 - Co-founder of Nordic Nanovectors A/S Oslo (with Medinnova) 
  • 2010 - Co-founder of Oncoinvent A/S, Oslo (with Inven2)
  • 2014 - Granted "The Innovation Price", Univeristy of Oslo; shared with Roy H Larsen

Research Supervision - Completed Theses: Main supervisor or co-supervisor for 16 candidates having completed their theses. Currently main supervisor for one candidate: Kjetil Berner, and co-supervisor for 3 PhD students:  Tale Barøy, Kristin Anfinsen and Ada Repetto (submitted).

Download CV in PDF format

 

 
[12892 visits]